Disappointing first study results of alum-GAD diabetes vaccine in children | ADA

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Why this matters

  • The vaccine, alum-formulated glutamate decarboxylase (alum-GAD), is being tested in children at high risk of developing type 1 diabetes (T1D), meaning that they have been found to have an ongoing autoimmune process but do not yet have any clinical symptoms of diabetes. 

Study design

  • Investigators at Lund University in Sweden recruited 50 participants from the age of four and followed them for five y.
  • Their goal was to evaluate the safety of two doses of alum-GAD administered subcutaneously to determine if it can delay or prevent the development of T1D. 

Key results

  • Levels of GAD autoantibodies increased significantly (P=.0014) ...